NCT02394314View on ClinicalTrials.gov

A Phase 1, Single Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

362

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Healthy Volunteers
Interventions
DRUG

MEDI0382

MEDI0382 administered subcutaneously

DRUG

Placebo

Placebo administered subcutaneously

Trial Locations (1)

Unknown

Research Site, Berlin

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY

NCT02394314 - A Phase 1, Single Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy Volunteers | Biotech Hunter | Biotech Hunter